Parmax Pharma [PARMAX] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Parmax Pharma Ltd.

BSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Parmax Pharma Ltd. wins in 6 metrics, Gujarat Themis Biosyn Ltd. wins in 11 metrics, with 0 ties. Gujarat Themis Biosyn Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Parmax Pharma Ltd. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) -5.63 73.73 Gujarat Themis Biosyn Ltd.
Price-to-Book Ratio -2.43 13.36 Gujarat Themis Biosyn Ltd.
Debt-to-Equity Ratio -2.38 27.04 Gujarat Themis Biosyn Ltd.
PEG Ratio -0.06 -17.55 Parmax Pharma Ltd.
EV/EBITDA 109.78 52.76 Gujarat Themis Biosyn Ltd.
Profit Margin (TTM) 15.84% 29.99% Gujarat Themis Biosyn Ltd.
Operating Margin (TTM) -6.82% 40.16% Gujarat Themis Biosyn Ltd.
EBITDA Margin (TTM) N/A 40.16% N/A
Return on Equity 105.30% 19.64% Parmax Pharma Ltd.
Return on Assets (TTM) -11.17% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $-16.59M $-251.22M Parmax Pharma Ltd.
Dividend Yield N/A 0.17% N/A
1-Year Return -18.44% 31.69% Gujarat Themis Biosyn Ltd.
Price-to-Sales Ratio (TTM) 0.42 22.23 Parmax Pharma Ltd.
Enterprise Value $197.87M $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 0.70 22.65 Parmax Pharma Ltd.
Gross Profit Margin (TTM) 28.35% 83.29% Gujarat Themis Biosyn Ltd.
Revenue per Share (TTM) $75 $15 Parmax Pharma Ltd.
Earnings per Share (Diluted) $-13.55 $4.40 Gujarat Themis Biosyn Ltd.
Beta (Stock Volatility) N/A -0.17 N/A

Parmax Pharma Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

PARMAX
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Parmax Pharma Ltd.-10.44%37.89%57.11%56.72%48.13%51.69%
Gujarat Themis Biosyn Ltd.0.38%2.15%10.93%43.75%6.59%-6.25%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Parmax Pharma Ltd.-18.44%19.45%-36.21%196.24%196.24%196.24%
Gujarat Themis Biosyn Ltd.31.69%84.69%84.69%84.69%84.69%84.69%

Performance & Financial Health Analysis: Parmax Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

MetricPARMAXGUJTHEM
Market Information
Market Cap i₹117.89M₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i39179,452
90 Day Avg. Volume i664106,446
Last Close₹45.73₹413.20
52 Week Range₹22.60 - ₹53.38₹225.05 - ₹479.00
% from 52W High-14.33%-13.74%
All-Time High₹81.90 (Jun 14, 2021)₹479.00 (Oct 27, 2025)
% from All-Time High-44.16%-13.74%
Growth Metrics
Quarterly Revenue Growth0.71%0.10%
Quarterly Earnings Growth-0.31%-0.04%
Financial Health
Profit Margin (TTM) i0.16%0.30%
Operating Margin (TTM) i-0.07%0.40%
Return on Equity (TTM) i1.05%0.20%
Debt to Equity (MRQ) i-2.3827.04
Cash & Liquidity
Book Value per Share (MRQ)₹-12.94₹24.29
Cash per Share (MRQ)N/A₹0.92
Operating Cash Flow (TTM) i₹-20,488,477₹970.68M
Levered Free Cash Flow (TTM) i₹-20,940,101₹487.72M
Dividends
Last 12-Month Dividend Yield iN/A0.17%
Last 12-Month Dividend iN/A₹0.67

Valuation & Enterprise Metrics Analysis: Parmax Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

MetricPARMAX (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-5.6373.73
Forward P/E iN/AN/A
PEG Ratio i-0.06-17.55
Price to Sales (TTM) i0.4222.23
Price to Book (MRQ) i-2.4313.36
Market Capitalization
Market Capitalization i₹117.89M₹35.41B
Enterprise Value i₹197.87M₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i0.7022.65
Enterprise to EBITDA i109.7852.76
Risk & Other Metrics
Beta iN/A-0.17
Book Value per Share (MRQ) i₹-12.94₹24.29

Financial Statements Comparison: Parmax Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPARMAX (2025)GUJTHEM (2025)
Revenue/Sales i282.04M1.51B
Cost of Goods Sold i237.36M318.78M
COGS % of Revenue i84.2%21.1%
Gross Profit i44.68M1.19B
Gross Margin i15.8%78.9%
Research & Development iN/A34.37M
Operating Income (EBIT) i-7.77M642.49M
Operating Margin i-2.8%42.6%
EBITDA i1.80M713.04M
EBITDA Margin i0.6%47.3%
Pre-Tax Income i-23.95M655.38M
Pre-Tax Income % of Revenue i-8.5%43.5%
Income Tax i-3.01M167.66M
Income Tax % of Revenue i-1.1%11.1%
Net Income (Profit) i-20.94M487.72M
Profit Margin i-7.4%32.3%

Balance Sheet & Liquidity Metrics

MetricPARMAX (2025)GUJTHEM (2025)
Cash & Equivalents i903,279116.94M
Total Current Assets i100.03M519.73M
Total Current Assets % of Revenue i35.5%34.5%
Total Current Liabilities i130.37M205.60M
Total Current Liabilities % of Revenue i46.2%13.6%
Long-Term Debt i77.04M296.36M
Long-Term Debt % of Revenue i27.3%19.7%
Total Shareholders Equity i-19.89M2.48B
Retained Earnings i-64.40M2.37B
Retained Earnings % of Revenue i-22.8%157.4%
Property, Plant & Equipment i17.29M411.30M

Cash Flow Statement Comparison

MetricPARMAX (2025)GUJTHEM (2025)
Operating Cash Flow i-20.49M970.68M
Operating Cash Flow % of Revenue i-7.3%64.4%
Capital Expenditures i-7.01M-1.16B
Free Cash Flow i-16.59M-251.22M
FCF Margin i-5.9%-16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPARMAXGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i3.74M108.97M
Float Shares iN/A29.52M
% Held by Insiders i64.25%71.98%
% Held by Institutions i0.00%1.18%
% Held by Public i35.75%26.84%

Dividend Analysis & Yield Comparison: Parmax Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

MetricPARMAXGUJTHEM
Last 12-Month Dividend iN/A₹0.67
Last 12-Month Dividend Yield iN/A0.17%
3-Year Avg Annual Dividend iN/A₹0.22
3-Year Avg Dividend Yield iN/A0.17%
3-Year Total Dividends iN/A₹0.67
Ex-Dividend DateN/ASep 04, 2025